NasdaqGM - Delayed Quote USD

ADMA Biologics, Inc. (ADMA)

Compare
21.18 -0.12 (-0.56%)
At close: November 22 at 4:00 PM EST
21.20 +0.02 (+0.09%)
After hours: 7:51 PM EST

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Adam S. Grossman Co-Founder, President, CEO & Director 1.59M -- 1977
Dr. Jerrold B. Grossman D.P.S., Ph.D. Co-Founder & Vice Chairman of the Board 90k -- 1948
Mr. Brad Tade CFO & Treasurer -- -- 1973
Ms. Kaitlin Kestenberg COO & Senior VP of Compliance -- -- 1987
Mr. Drew Pantello Vice President of Marketing & Corporate Development -- -- --
Mr. John Hafl Executive Director of Sales -- -- --
Ms. Cindy Petersen Vice President of Human Resources -- -- --
Mr. Skyler Bloom Senior Director of Business Development & Corporate Strategy -- -- --

ADMA Biologics, Inc.

465 State Route 17
Ramsey, NJ 07446
United States
201 478 5552 https://www.admabiologics.com
Sector:?
Healthcare
Industry:?
Biotechnology
Full Time Employees:?
624

Description

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Corporate Governance

ADMA Biologics, Inc.’s ISS Governance QualityScore as of November 1, 2024 is 7. The pillar scores are Audit: 8; Board: 6; Shareholder Rights: 8; Compensation: 7.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

November 7, 2024 at 9:05 PM UTC

ADMA Biologics, Inc. Earnings Date

Recent Events

November 21, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

November 8, 2024 at 12:00 AM UTC

SC 13G: Tender Offer/Acquisition Reports

November 7, 2024 at 9:30 PM UTC

Q3 2024 Earnings Call

November 7, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

October 31, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

October 17, 2024 at 12:00 AM UTC

SC 13G: Tender Offer/Acquisition Reports

October 10, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

October 9, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

September 17, 2024 at 7:05 PM UTC

at Cantor Global Healthcare Conference

August 14, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

Related Tickers